Across TCGA pan-cancer cohorts, TIGD1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TIGD1 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TIGD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TIGD1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM and LSCC are the cancer types where TIGD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.489	0.241	.009	8	view →
LSCC	DFS	Median	All	0.831	1.000	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TIGD1 tumor-vs-normal RNA expression · all TIGD1 data types